Shares of Cell Therepautics (CTIC) lose 11.6% in premarket trading after the firm announces that it entered an agreement where it will sell $20M of its Series 14 preferred shares and warrants in order to purchase common stock in a registered offering to 2 institutional investors.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs